+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating two strategies to prevent mother-to-child transmission of hepatitis B virus HBV by comparing a universal antiviral treatment approach with a selective strategy guided by a rapid point-of-care test for hepatitis B core-related antigen HBcrAg-RDT. This study focuses on pregnant women who are hepatitis B surface antigen HBsAg positive, particularly in low- and middle-income countries where viral load testing is often unavailable. The goal is to determine if the selective HBcrAg-RDT strategy is not less effective than the universal treatment strategy in reducing maternal viral load at childbirth, which is a key factor in transmission risk. Participants are divided into two groups one group receives immediate tenofovir disoproxil fumarate TDF antiviral treatment regardless of viral load universal strategy, while the other group undergoes HBcrAg-RDT testing and only those testing positive receive TDF selective strategy. TDF is administered orally at 300 mg daily or every two days if kidney function is reduced. Treatment starts during the inclusion visit and continues until 6 to 8 weeks after delivery. After three months postpartum, women undergo liver disease assessments including various blood tests, ultrasound, and further viral testing, with treatment resumption if needed according to updated guidelines. During the study, participants will attend antenatal care visits at rural or semi-rural primary health centers or hospitals. Their infants will be followed until 9 months old, including testing for HBV infection. The study also includes social science components in selected countries to assess acceptability, knowledge, treatment adherence, and policy factors. Researchers will measure the percentage of mothers with reduced viral load at delivery and the rate of infants positive for HBsAg at 9 months. The trial spans from 2026 to 2029, with detailed monitoring and evaluation of clinical, economic, and behavioral outcomes.

Age: 18Years - 50YearsFEMALEPhase Not Applicable
1 location
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
R

Actively Recruiting

Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
186 locations
R

Actively Recruiting

Researchers are evaluating the effects of the drug EYU688 compared with a placebo in adults aged 18 to 60 who have dengue fever. This study aims to understand how EYU688 influences dengue viral load, fever clearance time, and clinical symptoms. It is a phase 2 randomized, participant- and investigator-blinded, placebo-controlled trial with two parallel cohorts differing by pharmacokinetic sampling schedules. Participants will receive EYU688 or a matching placebo orally. The study includes two cohorts running simultaneously one with intensive pharmacokinetic sampling and one with sparse sampling, to assess the drugs behavior in the body. Treatment is administered during the initial days following fever onset, with careful monitoring of viral load and clinical signs. Throughout the study, participants will undergo regular assessments including viral load measurements, fever monitoring, clinical symptom evaluations, and laboratory tests such as blood counts and liver enzyme levels. Safety monitoring for adverse events will continue through Day 35. The primary outcome is reduction in viral load at 48 hours after treatment start. The total trial period includes follow-up until Day 35, with ongoing evaluation of clinical recovery and safety.

Age: 18Years - 60YearsAll GendersPhase 2
27 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of QMF149 a combination of indacaterol acetate and mometasone furoate compared to budesonide in children aged 6 to less than 12 years who have asthma. This Phase 3, double-blind, randomized, active-controlled crossover study aims to determine whether QMF149 is superior in improving lung function measured by FEV1 in these children, who have at least 50% of the predicted normal value of FEV1. Participants undergo two treatment periods, each lasting 12 weeks, receiving either QMF149 7540 mcg once daily via Breezhaler or budesonide 200 mcg once daily via Breezhaler in a crossover design. The study includes a screening period of up to 3 weeks, a 3-week run-in period with fluticasone propionate 50 mcg twice daily, a 3-week washout period with the same medication, and a 4-week safety follow-up during which participants return to standard care. The total study duration is up to 37 weeks. Throughout the study, participants will attend visits at defined intervals, including screening, run-in, treatment, washout, and follow-up periods. Researchers will assess lung function changes FEV1, asthma control questionnaire scores, peak expiratory flow rates, rescue medication use, and monitor adverse events. Safety information and survival status will be collected after the follow-up period to ensure thorough evaluation of both treatments.

Age: 6Years - 11YearsAll GendersPhase 3
65 locations
E

Actively Recruiting

Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.

Age: 12Years +All GendersPhase 2
186 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.

Age: 40Years - 80YearsAll GendersPhase 3
284 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations

1-10 of 22

1